CD274 and renal cell carcinoma: Based on the results of IMmotion151 trial for untreated metastatic RCC, the median PFS was 11·2 months in the atezolizumab plus bevacizumab group vs 7·7 months in the sunitinib group, in the PD‐L1 positive population (P = .022).11